A healing composition includes about 80 wt. % olive oil; about 15 wt. % kosher salt; and about 5 wt. % liquid rosemary. The healing composition is made by providing olive oil in a container; adding kosher salt to the container; adding liquid rosemary to the container; and mixing the olive oil, kosher salt, and liquid rosemary.

Microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. In relation to conventional oil-in-water (OIW) microemulsions, the described microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the MOIW microemulsion are modified with alcohol and can solubilize alcohol-soluble species, including nonderivatized hormones. More preferably, the modified oil phase droplets of the MOIW microemulsion directly solubilize nonderivatized hormones. The oil phase droplets of the MOIW microemulsion include DHEA, pregnenolone, and a polyphenol, where a ratio of DHEA to polyphenol is from 1:1 to 12:1 by weight. Methods of supporting and/or increasing bloodstream hormone levels in perimenopausal and postmenopausal females and improving menopausal symptoms also are disclosed.

Microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. In relation to conventional oil-in-water (OIW) microemulsions, the described microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the MOIW microemulsion are modified with alcohol and can solubilize alcohol-soluble species, including nonderivatized hormones. More preferably, the modified oil phase droplets of the MOIW microemulsion directly solubilize nonderivatized hormones. The oil phase droplets of the MOIW microemulsion include DHEA, pregnenolone, and a polyphenol, where a ratio of DHEA to polyphenol is from 1:1 to 12:1 by weight. Methods of supporting and/or increasing bloodstream hormone levels in perimenopausal and postmenopausal females and improving menopausal symptoms also are disclosed.

A method of treating vaginal dryness by administering a vaginal care composition, which includes an effective amount of a vaginal care agent, to vaginal tissue of a user experiencing vaginal dryness. The vaginal care agent may be selected to specifically treat symptoms of vaginal dryness exhibited by the introitus and/or labia, based on the transcriptomic data of skin cells obtained therefrom. In some instances, the vaginal care composition may be applied to introitus and/or labia with a suitable implement configured for such use.

A composition includes a cannabinoid agent in a range of 0.005% to 1%, a terpene agent in a range of 0.005% to 1%, and a co-fermented herbal complex in a range of 5% to 40%. The cannabinoid agent can include CBD, CBN, CBG, or a combination thereof. The composition can further include ashwagandha.

A composition includes a cannabinoid agent in a range of 0.005% to 1%, a terpene agent in a range of 0.005% to 1%, and a co-fermented herbal complex in a range of 5% to 40%. The cannabinoid agent can include CBD, CBN, CBG, or a combination thereof. The composition can further include ashwagandha.

A composition includes a cannabinoid agent in a range of 0.005% to 1%, a terpene agent in a range of 0.005% to 1%, and a co-fermented herbal complex in a range of 5% to 40%. The cannabinoid agent can include CBD, CBN, CBG, or a combination thereof. The composition can further include ashwagandha.

This disclosure relates to an enzymatic method including the steps of adding water to a reactor vessel with gentle mixing and minimal heating, adding osmotic protectant solution, adding plant material to the reactor, adding cell wall degrading enzymes at 0.1% wt/wt based on plant weight, heating the reactor now filled with plant material, osmotic protectant solution and enzyme blend solution to 30° C.-35° C., adding the enzyme mixture to the reactor and starting the timer for up to 2 hours, adding bulk density enhancer, further mixing the product, and drying the finished product containing protoplasts. The protoplast containing product may be provided in a dietary supplement for human use having antioxidant and anti-inflammatory properties.

The present disclosure provides a composition comprising (a) exosome-like nanovesicles or exosomes and (b) a carrier, wherein the exosome-like nanovesicles or exosomes are extracted from Withania somnifera and methods of effecting a change in hair appearance, hair growth, hair pigmentation, hair follicle size or hair shaft size, comprising administering to the skin of a subject in need thereof an effective amount of such a composition.

The present disclosure provides a composition comprising (a) exosome-like nanovesicles or exosomes and (b) a carrier, wherein the exosome-like nanovesicles or exosomes are extracted from Withania somnifera and methods of effecting a change in hair appearance, hair growth, hair pigmentation, hair follicle size or hair shaft size, comprising administering to the skin of a subject in need thereof an effective amount of such a composition.